Dual targeting of MAPK8 and JAK2 as a host-directed anti-inflammatory strategy for severe Klebsiella pneumoniae infection
-
Abstract
Severe Klebsiella pneumoniae empyema remains a therapeutic challenge because of complex host–pathogen interactions and frequent antibiotic failure. To dissect the underlying microenvironmental mechanisms and identify candidate therapeutics, we conducted a proof-of-concept single-patient study integrating longitudinal clinical multi-omics, single-cell spatial mapping, and virtual pharmacological screening. Untargeted metabolomics of pleural fluid revealed taurine-associated host-pathogen co-metabolism and identified a microbiota-specific reductase (K15373) as a computationally predicted metabolic vulnerability. Parallel transcriptomic network analysis identified a core signaling triad (MAPK8, JAK2, and TP53) associated with dysregulated inflammation, which was confirmed both in a K. pneumoniae lipopolysaccharide (LPS)-induced murine model of acute lung injury (ALI) and in longitudinal clinical pleural fluid samples. Projection of these targets onto a single-cell atlas of severe pulmonary infection revealed elevated expression in alveolar macrophages and type II pneumocytes, and a machine learning-based single-cell virtual knockout algorithm indicated that the hub genes contribute to cytokine release and epithelial barrier disruption. Network pharmacology and transcriptomic perturbation screening against large-scale databases then identified curcumin and evodiamine as candidate compounds that counteract the severe disease signature, and molecular dynamics simulations coupled with thermodynamic calculations predicted stable, high-affinity binding of curcumin to MAPK8 and of evodiamine to JAK2. We then evaluated the candidates in vivo in the K. pneumoniae LPS-induced murine ALI model. Given alone or in combination, curcumin and evodiamine attenuated body weight loss, pulmonary edema, alveolar-capillary barrier disruption, and histopathological injury. Western blot analysis showed that curcumin preferentially suppressed MAPK8/JNK phosphorylation, whereas evodiamine inhibited JAK2 phosphorylation, while combination therapy normalized both pathways; immunofluorescence revealed reduced infiltration of F4/80+ macrophages and Ly6G+ neutrophils. These results provide, to our knowledge, the first in vivo evidence that dual pharmacological inhibition of MAPK8 and JAK2 mitigates K. pneumoniae LPS-driven pulmonary inflammation. Overall, this computational systems biology approach characterizes the immunometabolic features of the infectious microenvironment and supports further medicinal chemistry optimization of curcumin- and evodiamine-based scaffolds as candidate dual-targeting agents, with particular attention to pharmacokinetic optimization and safety profiling.
-
-